| Systematic (IUPAC) name | |
|---|---|
| α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | B(US) |
| Legal status | ℞-only (US) Available on a named-patient basis (UK) |
| Routes | Intravenous |
| Identifiers | |
| CAS number | 25126-32-3 |
| ATC code | V04CC03 |
| PubChem | CID 32800 |
| UNII | M03GIQ7Z6P |
| KEGG | D05845 |
| ChEMBL | CHEMBL1121 |
| Synonyms | 1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl) amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl) carbamoyl]propanoic acid |
| Chemical data | |
| Formula | C49H62N10O16S3 |
| Mol. mass | 1143.27 g/mol |
| (what is this?) (verify) |
|
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.
Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.
|
|||||||||||||||||||||||||||||||||||||||